New survey shows nearly 80% of patients on warfarin want to self-monitor
A new survey from the Atrial Fibrillation society shows a high level of demand for self-monitoring in people being treated with warfarin.
Key results of the survey included:
- 78% agreed that convenience was an important factor in self-monitoring
- 64% believe that clinic visits impacted their time and finances
- 79% would prefer to self monitor over clinic visits
- 87% agreed that patient self monitoring is something they would consider
- 74% said that wireless connectivity to their clinic allowing them to take readings while travelling would be very appealing
Trudie Lobban MBE, Founder and CEO of the AF Association, said, “The results of the survey showed that patients want to self-monitor, giving them independence when travelling for work or pleasure. This innovation helps to empower patients to take control of their therapy and reduce the number of clinic visits that they have to make, saving both time and money”.
To coincide with the survey, two companies have launched products to support self-monitoring:
- The new CoaguChek INRange meter from Roche allows patients to send their results to their clinic via an App on their phone using wireless connectivity.
- The new engage product from LumiraDx Care Solutions delivers automated self-care for patients on warfarin therapy, allowing anticoagulation patients to self-test at home and send their INR details back to their clinic via an app. The product fully integrates with INRstar anticoagulation management software.